Comparison of DPP-4 Inhibitors / 임상당뇨병
Journal of Korean Diabetes
;
: 111-119, 2013.
Article
in Korean
| WPRIM
| ID: wpr-726957
ABSTRACT
During past several years, a novel class of antihyperglycemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, has become one of the most important options in the management of type 2 diabetes. These agents have unique insulinotropic actions as well as other advantages such as lower hypoglycemia and a weight-neutral effect compared to traditional insulin secretagogues. To date, 6 different DPP-4 inhibitors have been introduced sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin and gemiglitin. This review provides a summary of the clinical data for each DPP-4 inhibitor, and discusses the similarities and differences between them.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Piperidines
/
Purines
/
Pyrazines
/
Pyrrolidines
/
Quinazolines
/
Triazoles
/
Uracil
/
Adamantane
/
Diabetes Mellitus
/
Dipeptides
Language:
Korean
Journal:
Journal of Korean Diabetes
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS